- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01023243
Natural Language Processing and Quality Assessment in Primary Care
January 5, 2016 updated by: Steven Smith, Mayo Clinic
Novel Use of Natural Language Processing and Targeted Patient Education Information Regarding the Process for Completion of the Foot Examination in Primary Care
The investigators propose to use a Natural Language Processing System (NLP) to provide an initial baseline report for primary care patients at risk for diabetes and cardiovascular complications that will include: a) evidence of foot exam documentation in the previous year; b) use of aspirin for cardiovascular risk reduction; and c) tobacco use.
As part of a randomized trial, we plan to use a previously validated mailed survey (NCQA Provider Recognition Program) that requests information on the last foot exam, use of aspirin and tobacco.
Patients who have been identified by NLP as not having had a foot exam will be randomized into treatment and control arms.
Both arms will receive an informational letter; with a second mailing to nonresponders after one month, describing the key strategies for effective patient-physician communication during the clinical encounter.
The treatment arm will also receive an informational letter and patient education brochure containing key messages about the importance of regular foot examinations.
NLP will be repeated after 6 months to compare the impact of the patient education materials.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
389
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic Rochester
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- primary care patients with diagnosis of diabetes
Exclusion Criteria:
- unwilling to give informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: 1 CAre of the Feet for Those at Risk
secular trends for physician documentation in the medical record for care of the feet for high risk patients
|
Patient education materials and key messages for care of the feet for those patients at risk
Other Names:
NCQA Patient Survey
Other Names:
|
|
Active Comparator: Care of the feet for those at risk
the impact of 1) patient survey regarding last foot exam, tobacco and aspirin use on documentation of foot exam and 2) patient education material: Care of the Foot For Those at Risk, on documentation of foot examination in the medical record
|
NCQA Patient Survey
Other Names:
|
|
Active Comparator: Impact of Quality Survey
Impact of patient survey regarding last foot exam, tobacco and aspirin use on documentation of foot exam in the medical record
|
Patient education materials and key messages for care of the feet for those patients at risk
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Completion of foot exam
Time Frame: 6 months post intervention
|
6 months post intervention
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Patient report in validation of Natural Language Processing
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Gregory a Bartel, MD, Mayo Clinic
- Principal Investigator: Steven A Smith, MD, Mayo Clinic
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2010
Primary Completion (Actual)
April 1, 2011
Study Completion (Actual)
April 1, 2011
Study Registration Dates
First Submitted
December 9, 2008
First Submitted That Met QC Criteria
December 1, 2009
First Posted (Estimate)
December 2, 2009
Study Record Updates
Last Update Posted (Estimate)
January 6, 2016
Last Update Submitted That Met QC Criteria
January 5, 2016
Last Verified
January 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Aspirin
Other Study ID Numbers
- 08-002255
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of North Carolina, Chapel HillAmerican Diabetes AssociationNot yet recruitingType 2 Diabetes Mellitus (T2DM) | Diabetes (DM) | Insulin Dependent Diabetes | Type 1 Diabetes (T1D) | Diabetes Education | Diabetes Care | Diabetes (Insulin-requiring, Type 1 or Type 2)United States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Colorado, DenverMassachusetts General Hospital; Ann & Robert H Lurie Children's Hospital of... and other collaboratorsRecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin | Diabetes, Type IIUnited States
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
COUR Pharmaceutical Development Company, Inc.RecruitingType 1 Diabetes | Type 1 Diabetes Mellitus | T1DM | T1D | Type 1 Diabetes in Adolescence | Type 1 Diabetes in Children | Type 1 Diabetes Patients | Type 1 Diabetes Mellitis | T1DM - Type 1 Diabetes Mellitus | Type 1 Diabetes (Juvenile Onset)United States
-
Steno Diabetes Center CopenhagenNot yet recruitingDiabetes | Diabetes Type 1 | Diabetes Type 2 | Digital Health | Diabetes Care | Remote Patient MonitoringDenmark
Clinical Trials on Brochure: Care of the Feet for Those at Risk
-
Pakistan Institute of Living and LearningRecruitingIndividuals at Risk of First Episode PsychosisPakistan
-
University of California, DavisSacramento County Behavioral Health ServicesRecruitingClinical High Risk for Psychosis | Ultra High Risk for PsychosisUnited States
-
National Taiwan University HospitalCompleted
-
University Hospital, AntwerpRecruitingSepsis | Infection | Home Monitoring Follow-up | InnovativenessBelgium
-
Istanbul UniversityCompletedTherapeutic Procedural Complication
-
University of Maryland, BaltimoreNational Institute on Aging (NIA)Completed
-
Fondazione Don Carlo Gnocchi OnlusCompletedMalnutrition | RehabilitationItaly
-
Centre Hospitalier Universitaire, AmiensCompletedElderly | Knowledge, Attitudes, PracticeFrance
-
Queen's University, BelfastFour Seasons Health CareUnknownNeurodegenerative Diseases | DementiaUnited Kingdom